SLSSTOCK_USDT
幣種名稱 SLSSTOCK
流通率 0.00%
交易規則 (SLSUSDT Perpetual)
槓桿倍數 1 ~ 20
最小下單數量 1.269 USDT
市價單單筆最大下單數量 818.505 USDT
限價單單筆最大下單數量 818.505 USDT
最小變動價位 0.01
限價訂單價格上限/下限比例 10% / 10%
最大掛單數量 50
價差保護閾值 10%
合約面值 1 張 = 0.1 SLS
強平手續費率 0.02%
查看所有合約交易規則基於各類指標等數據計算得到的分析，用於輔助判斷買入和賣出訊號。
數值指標
| 名稱 | 數值 | 操作 |
|---|
| KDJ (9,3,3)_K | 82.0496 | 賣出 |
| KDJ (9,3,3)_D | 77.6185 | 賣出 |
| KDJ (9,3,3)_J | 90.912 | 賣出 |
| RSI (14) | 56.7383 | 賣出 |
| StochRSI (%K) | 99.1024 | 賣出 |
| StochRSI (%D) | 97.6689 | 賣出 |
多維度指標
| 名稱 | 操作 |
|---|
| KDJ (9,3,3)_K&D | 賣出 |
| KDJ (9,3,3) 金叉死叉 | 買入 |
| MACD (12,26,9) 金叉死叉 | 買入 |
| DEA 穿過零軸 | 賣出 |
| BOLL (20,2) 超買超賣 | 中立 |
| BOLL (20,2) 中軌金叉死叉 | 買入 |
總結: 賣出 8 · 中立 1 · 買入 17 — 買入
簡介
SEELAS Life Sciences Group, Inc. was incorporated in the State of Delaware on April 3, 2006, as Gold Rush Pharmaceuticals, Inc., and changed its name to REX Pharmaceuticals, Inc. on November 28, 2006. On September 26, 2011, the company changed its name to Galena Biopharmaceuticals, Ltd. Galena is a biotechnology company focused on discovering, developing, and commercializing innovative therapies to address major medical needs using targeted biologic therapies. Galena is pursuing the development of novel cancer therapeutics using peptide-based immunotherapy products, including its lead product candidate, the peptide (E75), for the treatment of breast cancer and other tumors. In patients with low-to-intermediate HER2-positive breast cancer who do not qualify for trastuzumab, the peptide is a peptide-based immunotherapy designed to reduce breast cancer recurrence rates.
Disclaimer: Data is collected from third-party platforms, provided for reference only, and does not constitute any form of investment advice or guarantee.
